In the SEER cohort, compared with patients who did not receive PMRT, those who received PMRT were younger, had a significantly higher proportion patients with married, infiltrating duct carcinoma, grade III, T2 stage tumor, three positive lymph nodes, LNR >15%, ER-negative, PR-negative, and received chemotherapy. The gene discussed is PGR; the disease is neoplasm.